This financial year has been one of increasing momentum for Noxopharm with three clinical studies underway, important additional programs being planned, and an expanding R&D program across a range of therapeutic indications. It is worth remembering that until we reach a point of generating ongoing revenue, the value of any drug development company lies in the strength of its intellectual property (IP). Developing IP and doing everything we can to protect that IP is our current business. Everything the Company has done this past year, and looks to do in the coming year, is about building its IP base to build sustainable and substantial shareholder value.
To view Report please download PDF attached:
Download this document